Title | Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Adult Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) |
---|---|
Disease/Condition | Sickle Cell |
Description | |
Eligibility Criteria | Click here for eligibility requirements |
Principal Investigator | Deepa Manwani, MD |
Contact Name | Karen Ireland |
Contact Email | kireland@montefiore.org |
Protocol Number | 17-02-348-01 |
Inclusion/Notes | This information was obtained from ClinicalTrials.gov. |
Adult Clinical Trial | Yes |
Pediatric Clinical Trial | No |
Adult, Pediatric, Both | Adult |